Advanced Life Sciences Names New Chief Financial
Richard Wieland, assumes role of EVP and CFO
Woodridge, Ill, Aug.10, 2004 - R. Richard Wieland, II, has
assumed the duties of executive vice president and chief financial
officer of Advanced Life Sciences (ALS), announced Michael T.
Flavin, ALS chairman and chief executive officer.
We are very pleased to have Rich Wieland on our team,” said
Flavin. “He has a very rich and deep pool of experience
with emerging biotechnology firms. He has worked with our management
team in the past and we believe that he is the right person to
help guide our company through the next phases of development.”
Prior to joining Advanced Life Sciences, Wieland served as executive
vice president and chief financial officer of MediChem Life Sciences
where he was responsible for overseeing financial operations
of MediChem and its subsidiaries.
He also assisted in the acquisitions
ThermoGen and Emerald Biostructures and in completing MediChem’s
initial public offering.
Wieland also spent eight years as senior vice president and chief
financial officer of LyphoMed (a $200 million NASDAQ-traded generic
pharmaceutical company) prior to its acquisition by Fujisawa
Pharmaceutical Co. Ltd. in Osaka, Japan. Earlier in his career,
in the financial management program at Proctor And Gamble. He
earned his Masters in Business Administration from Washington
in Saint Louis and his Bachelor of Arts degree in accounting
and economics at Monmouth College in Monmouth, Ill.
Advanced Life Sciences is a privately held biopharmaceutical company
engaged in the discovery, development and commercialization of
novel drugs in the therapeutic areas of infection, cancer and inflammation
using its platform in natural products and chemical proteomics
coupled with expertise in drug development. (www.advancedlifesciences.com)